The two-year turning point

Around the two-year mark, a pattern emerges that shapes virtually every cartilage decision in active patients: those treated with microfracture typically describe a good first year followed by a gradual return of symptoms, whilst those who have received a ChondroFiller injection report the opposite — scores still improving at three years, not retreating.

This divergence is not a marginal performance difference. The trajectories run in opposite directions after year two, and that is traceable to biology rather than chance. Three compounding mechanisms explain the gap. First, the type of repair tissue each approach produces differs in durability and load-bearing capacity. Second, microfracture carries a secondary risk to the subchondral bone beneath the repair — changes that further undermine structural integrity over time. Third, the two approaches address different patient populations entirely, so even their starting conditions are rarely equivalent.

Understanding these mechanisms matters because it changes how patients and clinicians weigh a decision made at a point when both options may still appear comparable.

What microfracture actually builds

Perforating the subchondral bone is the operative step in microfracture. The holes — typically spaced several millimetres apart — allow blood and marrow contents to flood the cartilage defect and form a clot. That clot eventually resolves into fibrocartilage: a tissue dominated by Type I collagen rather than the Type II collagen that characterises native hyaline cartilage.

The distinction matters because fibrocartilage is structurally softer, less wear-resistant, and less able to distribute compressive force across the joint surface. Hyaline cartilage's architecture — a dense, organised Type II matrix embedded with proteoglycans — evolved specifically for cyclic joint loading. Fibrocartilage has neither the tensile stiffness nor the surface lubrication to replicate that performance under repetitive load. The fill forms relatively quickly, which explains the genuine early improvement many patients experience, but the tissue begins to fatigue as soon as loading resumes in earnest.

That fatigue is not a slow plateau — it is a progressive structural failure. Clinical scores characteristically peak at around 12–18 months and then retreat, and long-term data bear this out: 16-year follow-up studies document symptom return and measurable OA progression in patients who underwent marrow stimulation alone. This makes the deterioration a time-dependent biological outcome rather than a matter of patient variability — a finding that has driven microfracture's declining use as evidence for more durable tissue-restoration approaches has accumulated.

Subchondral bone damage after microfracture

The fibrocartilage problem does not stand alone. Breaching the subchondral plate — the dense bone layer immediately beneath the cartilage — can trigger a secondary ossification response that imposes its own damage on the repair environment.

Published complication data show intralesional osteophyte formation in approximately 54% of microfracture patients by six months, rising to around 70% by twelve months. Bone cysts develop in up to 33% of cases. These are not rare adverse events; they are a predictable biological consequence of disturbing the subchondral architecture. When new bone forms within the defect site, it distorts the surface geometry beneath the fibrocartilage fill — a surface that was already mechanically limited. The result is compounded structural failure: bony irregularity transmits load unevenly through tissue that cannot withstand even uniform loading over the long term.

There is a further sequencing consideration. Subchondral plate disruption can narrow the options available if the initial repair fails and a more durable procedure becomes necessary; the altered bone bed is a less favourable substrate for second-line restoration techniques.

ChondroFiller injection sidesteps this mechanism entirely. Delivered into the joint space from above rather than through the bone, it does not breach the subchondral plate and leaves the underlying bone architecture intact.

How ChondroFiller injection builds differently

Unlike microfracture, ChondroFiller injection adds material to the joint without removing or breaching anything beneath it. The treatment is delivered as an ultrasound-guided outpatient injection — a 2.3 mL acellular murine Type I collagen scaffold that self-gels in situ on contact with the joint environment.

The scaffold itself contains no donor cells. Its role is chemotactic: once stable, it attracts the patient's own progenitor cells from surrounding tissue. Those cells migrate in, differentiate into chondrocytes, and begin producing a cartilage matrix. As that matrix matures and consolidates, the collagen scaffold progressively biodegrades, leaving behind repair tissue generated by the body's own biology — a process termed matrix-induced chondrogenesis.

This biological sequence produces a clinical trajectory that runs in the opposite direction to the microfracture arc described in the preceding sections. In the prospective post-market clinical follow-up study by Jerosch et al., mean IKDC scores improved by 32.4 points and continued to rise between the one-year and three-year assessments, reaching a functional score of approximately 80 at three years. Structural imaging reflects the same pattern: MOCART scores progressed from 65.3 at four weeks to 81.6 at one year, with European studies reporting a final range of 81.6 to 84.3 — indicating greater than 80% defect filling and good integration with surrounding native cartilage. The improving arc mirrors ongoing tissue consolidation rather than an early inflammatory peak followed by decline.

Which patients suit each approach

The fork between these two approaches is set largely by the character of the joint damage rather than by patient preference.

Microfracture suits a specific and relatively narrow profile: a focal, contained Grade III or IV cartilage defect, typically under 2 cm², with healthy surrounding borders. The joint must accommodate arthroscopic access and a dry operative field, and the patient is generally younger with a lower BMI — factors that determine how well fibrocartilage fill survives the mechanical demands placed on it.

ChondroFiller injection occupies a different — and in some respects broader — part of the indication landscape. Because the scaffold is delivered into a fluid joint environment via ultrasound-guided outpatient injection without disturbing the bone, it does not require the conditions microfracture demands. The standard treatable defect range extends to approximately 3 cm², with published evidence supporting extension to 6 cm² in appropriate cases. Crucially, it is used for diffuse Kellgren-Lawrence Grade III/IV osteoarthritis — a pattern of wear that makes marrow stimulation not just less effective but contraindicated.

For patients whose damage is too extensive, too diffuse, or whose surgical risk makes arthroscopy inadvisable, ChondroFiller injection represents a structural option that would not otherwise exist. The key clinical distinction is therefore not that one outperforms the other in the same patient — in many cases, they do not serve the same patient at all. Individual suitability depends on imaging, lesion grading, and specialist assessment.

What the evidence shows — and its current limits

The mechanistic case for why outcomes diverge is consistent across tissue biology, structural imaging, and clinical scoring — that direction is not in dispute. What the evidence cannot yet provide is a direct head-to-head randomised controlled trial; the comparison rests on separate evidence streams, and that distinction matters when weighing the data.

Three specific limits deserve naming plainly. The ChondroFiller injection outcome data — including the Jerosch PMCF study and the 2025 CER Version 09 — are predominantly from manufacturer-sponsored investigations; independent long-term RCT data are still developing. Published return-to-sport rates across cartilage procedures broadly sit at 76–78%, but equivalent athlete-specific data for ChondroFiller injection have not yet appeared in the literature. And whilst the focal-defect indication has accumulated meaningful follow-up, ChondroFiller injection use in diffuse Kellgren-Lawrence Grade III/IV osteoarthritis is a newer indication with less long-term evidence behind it.

These are genuine evidence asymmetries, not grounds to discount the underlying biology. The scaffold mechanism, the preservation of subchondral architecture, and the progressive MOCART and IKDC trajectories are consistent and reproducible findings across multiple studies. The limits concern trial design and follow-up duration — not whether the biological process functions as described.

What remains individual is suitability: lesion grade, joint health, age, and functional goals all shape which pathway, if either, applies. That determination requires a specialist cartilage assessment, of the kind the London Cartilage Clinic provides.

1. [1] Articular cartilage repair. https://en.wikipedia.org/?curid=19042351 https://en.wikipedia.org/?curid=19042351
2. [2] Knee cartilage replacement therapy. https://en.wikipedia.org/?curid=4984243 https://en.wikipedia.org/?curid=4984243
3. [3] Microfracture surgery. https://en.wikipedia.org/?curid=8840994 https://en.wikipedia.org/?curid=8840994